Skip to main content
. Author manuscript; available in PMC: 2019 Feb 22.
Published in final edited form as: Cell. 2018 Feb 22;172(5):1050–1062.e14. doi: 10.1016/j.cell.2018.01.038

Figure 4: CCL2 Overexpression in Human Leptomeningeal Metastases.

Figure 4:

a) CCL2 is differentially expressed between human primary and metastatic Group 3 medulloblastoma surgical samples as compared by expression microarray (p=0.041). See also Table S2. b) Expression of CCL2 is associated with metastatic status 2 and 3 in a cohort of 70 Grp3 MB with clinical annotation, 46.6% of M2/3 express CCL2 vs 20% in the M0/1 group. c) Human CCL2 resides on chromosome 17q, a region frequently gained in Group 3. Gain of chromosome 17q is significantly more common in patients with leptomeningeal dissemination for both Group 3 and Group 4 cohorts. In contrast, CCL2 expression is only marginally correlated with M2/3 in Shh patients, and the trend (23.5% CCL2 positive M1/0 vs 43.5% CLL2 positive) does not reach statistical significance (p=0.2462 Fisher’s exact test). d) 10q and 17q status as determined by 450K methylation array and 250K array (ONS76*)